Evidence map›Paper›PMID 27978817›Full record

ArticleBMC microbiology2016

Evaluation of Galleria mellonella larvae for studying the virulence of Streptococcus suis.

Nadya Velikova, Kevin Kavanagh, Jerry M Wells

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Decoding Virulence Mechanisms ofMicroorganisms · 2026
    Article
  3. Article
  4. Extracellular Vesicles fromMicroorganisms · 2025
    Article
  5. Antimicrobial photodynamic activity of a BODIPY on an alternative preclinical model Galleria mellonella.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Evaluating the In Vivo Virulence of EnvironmentalAntibiotics (Basel, Switzerland) · 2023
    Article
  11. Article
  12. Article
  13. Pathogenetic characterization of aFrontiers in pediatrics · 2023
    Article
  14. ACS infectious diseases · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Exogenous glycogen utilization effects the transcriptome and pathogenicity ofFrontiers in cellular and infection microbiology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Nadya VelikovaHost-microbe Interactomics Group, Department of Animal Sciences, Wageningen University, Zodiac 122, De Elst 1, 6708WD, Wageningen, The Netherlands. nadya.velikova@wur.nl.ORCID http://orcid.org/0000-0002-9183-4128
Kevin KavanaghDepartment of Biology, Maynooth University, Co. Kildare, Ireland.
Jerry M WellsHost-microbe Interactomics Group, Department of Animal Sciences, Wageningen University, Zodiac 122, De Elst 1, 6708WD, Wageningen, The Netherlands.
Wageningen University & Research · NLNational University of Ireland, Maynooth · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStreptococcus suis is an encapsulated Gram-positive bacterium and the leading cause of sepsis and meningitis in young pigs, resulting in considerable economic losses in the porcine industry. S. suis is considered an emerging zoonotic agent with increasing numbers of human cases over the last years. In the environment, both avirulent and virulent strains occur in pigs, with no evidence for consistent adapatation of virulent strains to the human host. Currently, there is an urgent need for a convenient, reliable and standardised animal model to rapidly assess S. suis virulence. Wax moth (Galleria mellonella) larvae have successfully been used in human and animal infectious disease studies. Here, we developed G. mellonella larvae as a model to assess virulence of S. suis strains.

resultsFourteen isolates of S. suis belonging to different serotypes killed G. mellonella larvae in a dose-dependent manner. Larvae infected with the virulent serotype 2 strain, S. suis S3881/S10, were rescued by antibiotic therapy. Crucially, the observed virulence of the different serotypes and mutants was in agreement with virulence observed in piglets (Sus scrofa) and the zebrafish larval infection model. Infection with heat-inactivated bacteria or bacteria-free culture supernatants showed that in most cases live bacteria are needed to cause mortality in G. mellonella.

conclusionsThe G. mellonella model is simple, cost-efficient, and raises less ethical issues than experiments on vertebrates and reduces infrastructure requirements. Furthermore, it allows experiments to be performed at the host temperature (37 °C). The results reported here, indicate that the G. mellonella model may aid our understanding of veterinary microbial pathogens such as the emerging zoonotic pathogen S. suis and generate hypotheses for testing in the target animal host. Ultimately, this might lead to the timely introduction of new effective remedies for infectious diseases. Last but not least, use of the G. mellonella infection model to study S. suis virulence adheres to the principles of replacement, reduction and refinement (3Rs) and can potentially reduce the number of vertebrates used for experimental infection studies.

Indexed as

AnimalsAnti-Bacterial AgentsDisease Models, AnimalLarvaMothsMutationStreptococcal InfectionsStreptococcus suisSus scrofaVirulenceZebrafishAnti-Bacterial AgentsGalleria mellonellaInfection modelReduction and refinement (3Rs)Streptococcus suisVirulence

Identifiers

PMID27978817
PMCPMC5160000
OpenAlexW2565168794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.